Sprache auswählen
Kostenlose Registrierung
Mein Warenkorb

HLA-A*0201 | B2M | EW

Produktanfrage

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
RogaratinibBAY-1163877Phase 3 ClinicalBayer AGSolid tumours; Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Breast Neoplasms; Gastrointestinal Stromal Tumors; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung
Details
SC-0011SC-0011Phase 3 ClinicalShijiazhuang Zhikang Hongren New Drug Development Co LtdSolid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
AUR-109ODM-203; AUR-109Phase 2 ClinicalOrion CorpOvarian Neoplasms; Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Pulmonary Fibrosis; Breast Neoplasms; Lung Neoplasms
Details
FisogatinibBLU-554; CS-3008Phase 2 ClinicalBlueprint Medicines CorpCarcinoma, Hepatocellular
Details
EVER-4010001EVER-4010001Phase 2 ClinicalEverNov Medicines (Zhuhai Hengqin) Co LtdSolid tumours
Details
GunagratinibICP-192Phase 2 ClinicalBeijing Tiancheng Pharmaceutical Technology Co LtdSolid tumours; Biliary Tract Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Cholangiocarcinoma; Lung Neoplasms
Details
IrpagratinibABSK-011Phase 2 ClinicalABbisko Therapeutics Co LtdSolid tumours; Liver Neoplasms; Carcinoma, Hepatocellular
Details
BPI-43487BPI-43487Phase 1 ClinicalBetta Pharmaceuticals Co LtdBiliary Tract Neoplasms; Solid tumours; Carcinoma, Hepatocellular
Details
HS-236HS-236Phase 1 ClinicalZhejiang Hisun Pharmaceutical Co LtdSolid tumours
Details
HS-10340HS-10340Phase 1 ClinicalChangzhou Hengbang Pharmaceutical Co Ltd, Shanghai Hansoh Biomedical Co Ltd, Jiangsu Hansoh Pharmaceutical Group Co LtdSolid tumours
Details
ICP-105ICP-105Phase 1 ClinicalNanjing Tianyin Jianhua Pharmaceutical Technology Co Ltd, Beijing Tiancheng Pharmaceutical Technology Co Ltd, Beijing Innocare Pharma Tech Co LtdLiver Neoplasms; Solid tumours
Details
ZSP-1241ZSP-1241Phase 1 ClinicalGuangdong Zhongsheng Pharmaceutical Co LtdBiliary Tract Neoplasms; Liver Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular
Details
H3B-6527H3B-6527Phase 1 ClinicalH3 Biomedicine IncLiver Neoplasms; Carcinoma, Hepatocellular
Details
SYHX-2005SYHX-2005; SYHX2005Phase 1 ClinicalCspc Ouyi Pharmaceutical Co LtdSolid tumours
Details
JAB-6343Phase 1 ClinicalJacobio Pharmaceuticals Co LtdSolid tumours
Details
SY-4798Phase 1 ClinicalSolid tumours
Details
ABSK-012ABSK-012; ABSK012Phase 1 ClinicalABbisko Therapeutics Co LtdSolid tumours
Details
LY-2874455LY-2874455Phase 1 ClinicalEli Lilly And CompanyNeoplasms; Leukemia, Myeloid, Acute
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
Lenvatinib MesylateMK-7902; ER-203492-00; E-7080ApprovedEisai Co LtdKisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛United StatesThyroid NeoplasmsEisai Inc2015-02-13Neuroendocrine Tumors; Paraganglioma; Thyroid Cancer, Papillary; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Glioma; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Breast Neoplasms; Cholangiocarcinoma; Osteosarcoma; Solid tumours; Carcinoma, Adenoid Cystic; Adenocarcinoma, Follicular; Liver Diseases; Thyroid Carcinoma, Anaplastic; Adenocarcinoma of Lung; Neoplasms; Renal Insufficiency; Pheochromocytoma; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Liver Neoplasms; Biliary Tract Neoplasms
Details
FutibatinibTAS-120ApprovedTaiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co LtdLYTGOBIUnited StatesCholangiocarcinomaTaiho Oncology Inc2022-09-30Central Nervous System Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Endometrial Neoplasms; Lymphoma; Metastatic breast cancer; Sarcoma; Cholangiocarcinoma; Breast Neoplasms; Biliary Tract Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Esophageal Neoplasms; Carcinoma; Stomach Neoplasms; Bone Marrow Neoplasms; Solid tumours
Details
Erdafitinib890E37NHMV; G-024; JNJ-493; JNJ-42756493; TAR-210ApprovedAstex Pharmaceuticals IncBalversaUnited StatesCarcinoma, Transitional CellJanssen Biotech Inc2019-04-12Carcinoma, Squamous Cell; Histiocytosis, Langerhans-Cell; Osteosarcoma; Sarcoma; Prostatic Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Histiocytic Sarcoma; Hepatic Insufficiency; Lymphoma; Lymphoma, Non-Hodgkin; Neuroblastoma; Glioma; Metastatic breast cancer; Carcinoma, Neuroendocrine; Carcinoma, Hepatocellular; Xanthogranuloma, Juvenile; Carcinoma, Non-Small-Cell Lung; Neoplasms, Germ Cell and Embryonal; Neuroectodermal Tumors, Primitive, Peripheral; Adenocarcinoma; Stomach Neoplasms; Rhabdomyosarcoma; Ependymoma; Medulloblastoma; Hematologic Neoplasms; Bone metastases; Carcinoma; Rhabdoid Tumor; Hepatoblastoma; Esophageal Neoplasms; Solid tumours; Glioblastoma; Carcinoma, Transitional Cell; Neoplasms; Wilms Tumor; Urinary Bladder Neoplasms; Multiple Myeloma; Central Nervous System Neoplasms; Prostatic Neoplasms, Castration-Resistant; Sarcoma, Ewing
Details
  • Produktanfrage
  • Inverkehr gebrachte Arzneimittelinformation
  • Klinische Arzneimittelinformation
Teilen auf:

Mach mitRechtliche HinweiseSeitenübersichtDatenschutzrichtlinieTerms and Conditions
Website-Feedback
Kontaktieren Sie uns

+49 800 0826645

order.de@acrobiosystems.com
tech.de@acrobiosystems.com

BettinastraBe 30, 60325 Frankfurt am Main